MA53648A - Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase - Google Patents
Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidaseInfo
- Publication number
- MA53648A MA53648A MA053648A MA53648A MA53648A MA 53648 A MA53648 A MA 53648A MA 053648 A MA053648 A MA 053648A MA 53648 A MA53648 A MA 53648A MA 53648 A MA53648 A MA 53648A
- Authority
- MA
- Morocco
- Prior art keywords
- glucopyranosidase
- desoxy
- acetamido
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733484P | 2018-09-19 | 2018-09-19 | |
| US201862750000P | 2018-10-24 | 2018-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53648A true MA53648A (fr) | 2021-07-28 |
Family
ID=68073263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053648A MA53648A (fr) | 2018-09-19 | 2019-09-18 | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220041586A1 (fr) |
| EP (1) | EP3853226A1 (fr) |
| JP (1) | JP2022500472A (fr) |
| KR (1) | KR20210060513A (fr) |
| CN (1) | CN113166137B (fr) |
| AU (1) | AU2019344922A1 (fr) |
| BR (1) | BR112021004739A2 (fr) |
| CA (1) | CA3113009A1 (fr) |
| CL (1) | CL2021000646A1 (fr) |
| CO (1) | CO2021004873A2 (fr) |
| CR (1) | CR20210181A (fr) |
| IL (1) | IL281514B1 (fr) |
| JO (1) | JOP20210036A1 (fr) |
| MA (1) | MA53648A (fr) |
| MX (1) | MX2021003232A (fr) |
| PE (1) | PE20211591A1 (fr) |
| PH (1) | PH12021550439A1 (fr) |
| SG (1) | SG11202102379XA (fr) |
| TW (1) | TW202031651A (fr) |
| UY (1) | UY38376A (fr) |
| WO (1) | WO2020061150A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002013A2 (pt) * | 2020-08-03 | 2023-05-02 | Biogen Ma Inc | Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2780013A4 (fr) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2013078320A1 (fr) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| TWI629273B (zh) | 2013-02-11 | 2018-07-11 | 美商星宿藥物公司 | 甲基修飾酵素之調節劑、其組成物及用途 |
| AU2014241065B2 (en) * | 2013-03-14 | 2017-08-31 | Merck Patent Gmbh | Glycosidase inhibitors |
| WO2014151142A1 (fr) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2018109198A1 (fr) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga bicyclique |
| EP3555087A1 (fr) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Composés inhibiteurs d'oga monocyclique |
| AR110747A1 (es) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
| WO2019178191A1 (fr) * | 2018-03-14 | 2019-09-19 | Biogen Ma Inc. | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase |
-
2019
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/ko unknown
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/fr active Pending
- 2019-09-18 CN CN201980060829.1A patent/CN113166137B/zh active Active
- 2019-09-18 CR CR20210181A patent/CR20210181A/es unknown
- 2019-09-18 IL IL281514A patent/IL281514B1/en unknown
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/es unknown
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/ar unknown
- 2019-09-18 US US17/276,502 patent/US20220041586A1/en active Pending
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/es unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/pt unknown
- 2019-09-18 TW TW108133538A patent/TW202031651A/zh unknown
- 2019-09-18 UY UY0001038376A patent/UY38376A/es unknown
- 2019-09-18 AU AU2019344922A patent/AU2019344922A1/en active Pending
- 2019-09-18 MA MA053648A patent/MA53648A/fr unknown
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/fr active Application Filing
- 2019-09-18 JP JP2021515045A patent/JP2022500472A/ja active Pending
- 2019-09-18 CA CA3113009A patent/CA3113009A1/fr active Pending
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/es unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/es unknown
-
2024
- 2024-05-24 US US18/673,619 patent/US20240308995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166137A (zh) | 2021-07-23 |
| JOP20210036A1 (ar) | 2021-02-25 |
| WO2020061150A1 (fr) | 2020-03-26 |
| IL281514B1 (en) | 2024-10-01 |
| CN113166137B (zh) | 2024-08-16 |
| SG11202102379XA (en) | 2021-04-29 |
| PH12021550439A1 (en) | 2021-11-29 |
| US20220041586A1 (en) | 2022-02-10 |
| PE20211591A1 (es) | 2021-08-18 |
| CA3113009A1 (fr) | 2020-03-26 |
| CR20210181A (es) | 2021-07-01 |
| CO2021004873A2 (es) | 2021-07-30 |
| KR20210060513A (ko) | 2021-05-26 |
| JP2022500472A (ja) | 2022-01-04 |
| UY38376A (es) | 2020-04-30 |
| US20240308995A1 (en) | 2024-09-19 |
| EP3853226A1 (fr) | 2021-07-28 |
| MX2021003232A (es) | 2021-07-16 |
| IL281514A (en) | 2021-04-29 |
| BR112021004739A2 (pt) | 2021-06-01 |
| CL2021000646A1 (es) | 2021-09-03 |
| TW202031651A (zh) | 2020-09-01 |
| AU2019344922A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| DK3737403T5 (da) | Modificerede adenovira | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| DK3738452T3 (da) | Fordamper | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA53009A (fr) | Agents inhibiteurs d'ask1 | |
| IT201700035964A1 (it) | “divisorio per boiserie” | |
| MA55203A (fr) | Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase | |
| ES1243687Y (es) | Salmorejo | |
| IT201800009293A1 (it) | "divano" | |
| IT201900020430A1 (it) | Espositore |